ASO Author Reflections: Predicting the Response of Esophageal Adenocarcinoma to Chemoradiotherapy Before Surgery Using MicroRNA Biomarkers Offers Hope to Improve Outcomes by Tailoring Treatment to Predicted Responses
- 35 Downloads
Treatment for locally advanced esophageal adenocarcinoma usually involves neoadjuvant chemotherapy or chemoradiotherapy, followed by surgical resection. Neoadjuvant treatment improves survival rates, but only 30% of patients have complete pathological response, and survival is improved in only 10–15% of patients compared with surgery alone.1 Furthermore, neoadjuvant chemoradiotherapy can increase morbidity and make some patients unfit for surgery. Whilst some patients do benefit from neoadjuvant therapies, many more might actually be subjected to treatment toxicity and have their surgery delayed for no survival advantage.
As clinicopathological factors are not sufficiently accurate to predict which patients will actually benefit versus not benefit from neoadjuvant therapy, it has been suggested that future research should focus on molecular classifiers.2MicroRNAs (miRNAs) are small noncoding RNAs that are known to be important in directing the behavior of cancers, including...
The authors have no conflicts of interest to disclose.
- 2.Blum Murphy M, Xiao L, Patel VR, et al. Pathological complete response in patients with esophageal cancer after the trimodality approach: the association with baseline variables and survival—The University of Texas MD Anderson Cancer Center experience. Cancer 2017;123(21):4106–13.CrossRefGoogle Scholar